Table 3.
Blastocysts recorded at different time points after microinjection of siCDC5L into GV oocytes followed by maturation and parthenogenetic activation
Control, without microinjection; NC, microinjected negative control; siCDC5L, microinjected cdc5l siRNAs. a-b and A-B indicate significant differences at p < 0.05 and p < 0.01 levels within the same subcolumns, respectively.
| Group | Total No. embryos | Total No. balstocyst | No. blastocoelic balstocyst | No. expanded blastocyst | No. hatched blastocyst | |
|---|---|---|---|---|---|---|
| % ± S.D. | ||||||
| Day 5 | Control | 132 | 40 (29.7 ± 6.3%) | 18 (13.1 ± 3.8%) | 22 (16.6 ± 4.1%) | 0 |
| NC | 131 | 41 (30.9 ± 2.6%) | 20 (15.0 ± 5.0%) | 21 (15.9 ± 3.6%) | 0 | |
| siCDC5L | 137 | 29 (20.2 ± 8.4%) | 15 (10.4 ± 3.7%) | 14 (9.8 ± 5.1%) | 0 | |
| Day 6 | Control | 132 | 57 (42.7 ± 4.3%)A | 15 (11.4 ± 0.7%) | 34 (25.6 ± 3.6%) | 8 (5.7 ± 2.5%) |
| NC | 131 | 54 (41.2 ± 2.3%)A | 14 (10.9 ± 2.7%) | 34 (25.4 ± 3.1%) | 6 (4.8 ± 1.3%) | |
| siCDC5L | 137 | 35 (26.2 ± 7.0%)B | 11 (9.2 ± 6.0%) | 21 (15.1 ± 3.9%) | 3 (2.0 ± 3.4%) | |
| Day 7 | Control | 132 | 61 (45.8 ± 5.0%)A | 15 (11.4 ± 1.5%) | 35 (26.5 ± 1.1%) | 11 (7.8 ± 4.2%) |
| NC | 131 | 57 (43.2 ± 4.1%)A | 17 (12.9 ± 1.5%) | 32 (24.1 ± 2.0%) | 8 (6.2 ± 2.2%) | |
| siCDC5L | 137 | 35 (27.5 ± 6.8%)B | 13 (10.4 ± 5.0%) | 21 (15.1 ± 3.9%) | 3 (2.0 ± 3.4%) | |